Xilio Therapeutics Inc (NASDAQ: XLO) Loses -70.57% From High. Why That Could Change?

Currently, there are 27.43M common shares owned by the public and among those 13.85M shares have been available to trade.

The company’s stock has a 5-day price change of 53.74% and 96.51% over the past three months. XLO shares are trading 96.36% year to date (YTD), with the 12-month market performance down to -65.27% lower. It has a 12-month low price of $0.49 and touched a high of $3.67 over the same period. XLO has an average intraday trading volume of 225.67K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 50.79%, 62.37%, and -35.73% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Xilio Therapeutics Inc (NASDAQ: XLO) shares accounts for 15.44% of the company’s 27.43M shares outstanding.

It has a market capitalization of $29.74M and a beta (3y monthly) value of -0.27. The earnings-per-share (ttm) stands at -$2.96. Price movements for the stock have been influenced by the stock’s volatility, which stands at 25.88% over the week and 17.69% over the month.

Analysts forecast that Xilio Therapeutics Inc (XLO) will achieve an EPS of -$0.64 for the current quarter, -$0.82 for the next quarter and -$3.1 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.7 while analysts give the company a high EPS estimate of -$0.55. Comparatively, EPS for the current quarter was -$0.82 a year ago. Earnings per share for the fiscal year are expected to increase by 14.70%, and 25.73% over the next financial year.

Looking at the support for the XLO, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on December 21, 2022, with the firm’s price target at $7. H.C. Wainwright coverage for the Xilio Therapeutics Inc (XLO) stock in a research note released on January 10, 2022 offered a Buy rating with a price target of $36. Raymond James was of a view on November 16, 2021 that the stock is Outperform, while Morgan Stanley gave the stock Overweight rating on November 16, 2021, issuing a price target of $32. Guggenheim on their part issued Buy rating on November 16, 2021.

Most Popular

Related Posts